Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Aurobindo Pharma Limited — Q1 FY26
Aurobindo Pharma reported a steady Q1 FY26 with consolidated revenue of INR 7,878 crore (+4% YoY) and EBITDA of INR 1,603 crore (+12% YoY), despite a significant reduction in generic Revlimid sales (down ~INR 150 crore YoY).
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Aurobindo Pharma reported a steady Q1 FY26 with consolidated revenue of INR 7,878 crore (+4% YoY) and EBITDA of INR 1,603 crore (+12% YoY), despite a significant reduction in generic Revlimid sales (down ~INR 150 crore YoY). EBITDA margin held at 20.4%, supported by favorable mix and cost controls. European formulations grew 9% YoY to €241 million, while the U.S. business declined 4% due to Revlimid erosion and temporary destocking. API revenue fell 16% YoY on pricing pressure. Management maintained FY26 EBITDA margin guidance of 20-21%, driven by ramp-up of the PNG plant (resumed July 1) and new capacity additions. Key risks include sustained API pricing pressure and FTC approval delays for the Lannett acquisition.
ऑरोबिंदो फार्मा ने पहली तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 7,878 करोड़ रुपये रही, जो पिछले साल से 4% ज्यादा है। मुनाफा (EBITDA) 1,603 करोड़ रुपये रहा, जो 12% बढ़ा। हालांकि, जेनेरिक रेवलिमिड दवा की बिक्री 150 करोड़ रुपये घटी, फिर भी कंपनी ने लागत कम करके और सही उत्पाद मिश्रण से 20.4% मुनाफा मार्जिन बनाए रखा। यूरोप में दवा बिक्री 9% बढ़ी, लेकिन अमेरिका में 4% गिरी। एपीआई (दवा का कच्चा माल) बिक्री 16% घटी। कंपनी को उम्मीद है कि नए पीएनजी प्लांट से मुनाफा 20-21% रहेगा। जोखिम: एपीआई की कीमतें गिर सकती हैं और लैनेट कंपनी खरीदने में देरी हो सकती है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Sustained API pricing pressure
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
European Formulation Revenue
€241M
+9% YoY
European business continued strong trajectory, crossing €1B annual run-rate milestone.
U.S. Injectable Sales QoQ Growth
11%
+11% QoQ
Injectable sales grew quarter-on-quarter, indicating recovery from prior disruptions.
New Product Launches in U.S.
15
N/A
Launched 15 new products in the U.S. during the quarter, supporting base business.
Net Cash Position
$140M
+$98M QoQ
Net cash improved from $42M in March 2025, reflecting deleveraging and cash generation.
What Changed vs Last Quarter
NEW
FY26 EBITDA margin target of 20-21%
Management reiterated internal target margin range of 20-21% for FY26, supported by volume expansion and new site ramp-up.
NEW
China facility to break even at EBITDA by Q3 FY26
The China facility, with initial capacity of 2 billion+ units, is expected to break even at EBITDA level by Q3 FY26.
NEW
PNG plant to generate healthy EBITDA from Q3 FY26
The PNG plant resumed operations and is expected to generate healthy EBITDA from Q3 onwards as yields improve.
NEW
European business to cross €1B annual revenue by FY26 end
Management expects European formulations to exceed €1 billion in annual revenues by the end of FY26.
DROPPED
High single-digit revenue growth in FY26 excluding transient products
Management expects revenue growth of 8-9% in FY26, excluding the contribution from transient products like Revlimid.
DROPPED
Maintain current EBITDA margins in FY26
The company internally aims to keep EBITDA margins at present levels (around 20.8%) for FY26.
DROPPED
China OSD plant to contribute revenues in FY26
The China plant, commercialized in FY25, is expected to contribute revenues in FY26 and turn breakeven or slightly positive.
DROPPED
US Dayton OSD plant commercialization in Q2 FY26
The US-based OSD plant at Dayton is expected to commence commercial manufacturing in Q2 of FY26.
NEW RISK
Sustained API pricing pressure
API revenue declined 16% YoY due to pricing pressure from both domestic and import competition, which may persist.
NEW RISK
FTC approval delay for Lannett acquisition
The Lannett acquisition is subject to FTC approval, which could take 8-12 months or longer, delaying synergies.
NEW RISK
Generic Revlimid revenue tailwind fading
Generic Revlimid sales have largely been exhausted, with minimal future contribution expected, impacting U.S. revenue.
NEW RISK
U.S. tariff and domestic manufacturing push uncertainty
Potential U.S. tariffs and push for domestic manufacturing could increase costs and alter competitive dynamics.
RISK GONE
Pen-G plant fire disruption
A fire incident at the Pen-G facility in Kakinada has halted production; resumption depends on regulatory approvals, impacting FY26 revenue and margin assumptions.
RISK GONE
Potential US tariffs on pharmaceutical imports
Tariff announcements expected in July 2025 could impact US business; management declined to provide specific guidance until clarity emerges.
RISK GONE
Muted injectable growth in FY26 due to Eugia-3 remediation
Eugia-3 facility remains under FDA remediation; injectable growth is expected to be flat in FY26, with recovery only in FY27.
RISK GONE
Revlimid revenue decline in FY26
Revenue from Revlimid will be significantly lower in FY26 as the product faces increased competition and limited remaining supply.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY25, Q3 FY25
Omalizumab and ophthalmic product trials are delayed; ophthalmic recruitment only 50% and expected to complete in H2 2026, pushing back potential launches.
Mentioned in Q1 FY25, Q3 FY25
The China OSD plant (2B units capacity) commercialized in November 2024, expected to ramp up and contribute to revenues in FY26, initially supplying Europe.
Mentioned in Q3 FY25, Q4 FY25
The US-based OSD plant at Dayton is expected to commence commercial manufacturing in Q2 of FY26.
Fast read
Guidance and risk preview
Management reiterated internal target margin range of 20-21% for FY26, supported by volume expansion and new site ramp-up.
API revenue declined 16% YoY due to pricing pressure from both domestic and import competition, which may persist.
View Risks →